Kucera Pharmaceutical Announces Discovery Of A Novel Antiviral Compound For The Potential Treatment Of Severe Acute Respiratory Syndrome (SARS) 
10/19/2005 5:10:17 PM

WINSTON-SALEM, N.C., March 4 /PRNewswire/ -- The Kucera Pharmaceutical Co. announced today it has within its armamentarium a novel antiviral compound that has confirmed activity against the causative viral agent responsible for SARS. Patents on this use and other antiviral applications were recently filed.

"The preliminary data obtained through independent laboratory testing are encouraging and support the continued development of this novel antiviral compound," said Dr. Ronald A. Fleming, the company's Chief Scientific Officer.

"This company has a large inventory of powerful antiviral and anticancer agents," said Russ H. Read, CEO. "We are steadily moving forward the candidate drugs discovered within our platform so they can be licensed out for final development and commercialization."

Kucera Pharmaceutical Co., an award-winning North Carolina-based biotechnology company ( ), is a 2001 spin-off of Wake Forest University Health Sciences and the University of North Carolina at Chapel Hill. It has in development patented novel antiviral and anti-cancer agents.

Kucera is headquartered at the Piedmont Triad Research Park ( ) in downtown Winston-Salem and has laboratories in Durham, N.C.

CONTACT: Russ H. Read, CEO Kucera Pharmaceutical Co. (336) 723-7133 Dr. Ronald A. Fleming Chief Scientific Officer Kucera Pharmaceutical Co. (336) 403-6819

Kucera Pharmaceutical Co.

CONTACT: Russ H. Read, CEO, +1-336 723-7133, or Dr. Ronald A. Fleming,Chief Scientific Officer, +1-336-403-6819, both of Kucera Pharmaceutical Co.